| 001 | 305755 | ||
| 005 | 20251113115742.0 | ||
| 024 | 7 | _ | |a 10.1002/pbc.32159 |2 doi |
| 024 | 7 | _ | |a pmid:41216926 |2 pmid |
| 024 | 7 | _ | |a 1545-5009 |2 ISSN |
| 024 | 7 | _ | |a 1545-5017 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02375 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Heinz, Amadeus T |0 0000-0003-3472-9679 |b 0 |
| 245 | _ | _ | |a Children and Adolescents With Localised Non-Rhabdomyosarcoma Soft Tissue Sarcoma: Results of the CWS-96 and CWS-2002P Prospective Trials With Reclassification of the Trial Data Incorporating the Recent Soft Tissue Sarcoma Registry. |
| 260 | _ | _ | |a New York, NY |c 2025 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1762960153_3281639 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:B062# / epub |
| 520 | _ | _ | |a Here we report the results of the first comprehensive European trials for all soft tissue sarcoma entities, which aimed to develop a new risk stratification system, limit radiotherapy and chemotherapy for low-/standard-risk patients, and evaluate different chemotherapy regimens for high-risk patients.The prospective CWS-96 and CWS-2002P trials stratified patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) by Intergroup Rhabdomyosarcoma Study (IRS) group, histology and grade (CWS-96) or IRS group, lymph node status, tumour histology and size (CWS-2002P). Low-risk patients received no additional treatment. Standard-risk patients were treated with 44.8 Gy radiotherapy, and in CWS-96, adjuvant chemotherapy was added for high-grade tumours (vincristine, actinomycin-D, ifosfamide, 160-240 mg/m2 adriamycin/VAIA). High-risk patients received VAIA in CWS-96 or an intensified adriamycin regimen in CWS-2002P (VAIA-III, 320 mg/m2 adriamycin), resection and/or 44.8 Gy radiotherapy, followed by maintenance treatment with cyclophosphamide and vinblastine in certain NRSTS in CWS-2002P. The trials enrolled 1249 patients with localised NRSTS, of whom 483 (CWS-96) and 445 (CWS-2002P) were eligible for survival analysis. Histological classifications were retrospectively standardised, including recent data from the soft tissue sarcoma registry.Overall survival (OS) was significantly improved (5-year OS: 81% vs. 73%, p = 0.024) for patients treated in CWS-2002P compared to CWS-96, partly explained by the inclusion of more low-grade entities in CWS-2002P. The higher anthracycline dose in the VAIA-III regimen (CWS-2002P) did not improve survival (EFS: p = 0.23, OS: p = 0.73; matched pairs analysis). Re-classification revealed a higher proportion of malignant entities according to WHO in CWS-96 compared to CWS-2002P (90% vs. 81%, p < 0.001).Complete resection alone is sufficient to cure low-risk NRSTS. Survival was not improved by dose-intensified adjuvant chemotherapy (with/without maintenance treatment). Patients with completely resected high-risk disease may not profit from adjuvant radiotherapy. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a CWS‐2002P |2 Other |
| 650 | _ | 7 | |a CWS‐96 |2 Other |
| 650 | _ | 7 | |a anthracyclines |2 Other |
| 650 | _ | 7 | |a chemotherapy |2 Other |
| 650 | _ | 7 | |a long‐term sequelae |2 Other |
| 650 | _ | 7 | |a maintenance treatment |2 Other |
| 650 | _ | 7 | |a non‐rhabdomyosarcoma soft tissue sarcoma |2 Other |
| 650 | _ | 7 | |a pediatric/adolescent oncology |2 Other |
| 650 | _ | 7 | |a radiotherapy |2 Other |
| 650 | _ | 7 | |a surgery |2 Other |
| 700 | 1 | _ | |a Schönstein, Anton |b 1 |
| 700 | 1 | _ | |a Koscielniak, Ewa |b 2 |
| 700 | 1 | _ | |a Ebinger, Martin |0 0000-0002-4229-8058 |b 3 |
| 700 | 1 | _ | |a Fuchs, Jörg |b 4 |
| 700 | 1 | _ | |a Harrabi, Semi |b 5 |
| 700 | 1 | _ | |a Vokuhl, Christian |0 0000-0002-4138-4536 |b 6 |
| 700 | 1 | _ | |a Imle, Roland |0 P:(DE-He78)3c021852cf94cb29825e65baa82ed54b |b 7 |u dkfz |
| 700 | 1 | _ | |a Stegmaier, Sabine |0 0000-0001-7281-8811 |b 8 |
| 700 | 1 | _ | |a Brecht, Ines B |b 9 |
| 700 | 1 | _ | |a Ljungman, Gustaf |b 10 |
| 700 | 1 | _ | |a Juntti, Hanna |b 11 |
| 700 | 1 | _ | |a Ladenstein, Ruth |b 12 |
| 700 | 1 | _ | |a Kazanowska, Bernarda |b 13 |
| 700 | 1 | _ | |a Klingebiel, Thomas |b 14 |
| 700 | 1 | _ | |a Pajtler, Kristian |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |b 15 |e Last author |u dkfz |
| 700 | 1 | _ | |a Sparber-Sauer, Monika |0 0000-0001-9551-2399 |b 16 |
| 773 | _ | _ | |a 10.1002/pbc.32159 |g p. e32159 |0 PERI:(DE-600)2130978-4 |p nn |t Pediatric blood & cancer |v nn |y 2025 |x 1545-5009 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:305755 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)3c021852cf94cb29825e65baa82ed54b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2024-12-31 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PEDIATR BLOOD CANCER : 2022 |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-31 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-31 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-31 |
| 920 | 2 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B380-20160331 |k B380 |l NWG Weichteilsarkome |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B380-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::